According to a University of Colorado Cancer Center study published this week in the Journal of Clinical Oncology, a decade that saw the development of new therapies for non-small cell lung cancer resulted in little survival benefit for patients with advanced-stage disease. In 22,163 patients treated between 2000 and 2011 with newly approved therapies including pemetrexed, erlotinib, or bevacizumab, survival increased by a median 1.5 months. Because these drugs were used in place of older chemotherapies and there was a declining trend in surgeries, inpatient spending fell about $5,600 per person, but this was more than offset by the cost of these new medicines, which raised outpatient spending by about $8,800 per person.
“As new therapies were introduced, they were rapidly adopted and the old therapies were abandoned. Across the population in the past 12 years, these newly approved therapies have made little difference in overall survival,” says Cathy Bradley, PhD, associate director for population sciences research at CU Cancer Center.
Unlike clinical trial results, the current study looks beyond the optimal application of these drugs to their use in the real world. For example, Bradley points out, many of these targeted therapies are only useful when directed at a cancer with a specific biomarker but may be used irrespective of biomarker status.
“Take erlotinib,” says Bradley. “A patient’s tumor must by marked by EGFR for it to be beneficial. But when some patients reach the end of their established options, some oncologists may prescribe erlotinib without the EGFR biomarker in hopes that the patient will benefit.”
The decision can be costly. Patients with cancer are 2.5 times more likely to declare bankruptcy than patients who have not had cancer. Bradley points out that in an era of rising drug costs and a higher financial burden placed on patients, treatment often costs $30-40K in out-of-pocket expenses.
“When you talk with patients, leaving their family in financial distress is an important concern,” Bradley says.
As Bradley sees it, the challenge of these new medicines is to optimize their value by using them in the population most likely to benefit while working with patients to better understand the costs associated with treatment that may have little or no impact on survival.
“What we see here doesn’t definitively mean these drugs are unsuccessful. It means that despite their promise in clinical trials, they haven’t made a survival difference in the population. That may be because oncologists are giving them to people who will not benefit. Better predicting who will benefit from newer more expensive therapies is essential to making value-based decisions in the context of very high costs and new medicines,” Bradley says.